Medicine. The need for a global HIV vaccine enterprise

A new collaborative model of research is needed to increase resources, to prioritize the R (ii) to increase the pace, reduce the overlap, and more systematically explore the elements of and delivery systems for vaccines; (iii) to use common standards for the prompt comparative testing of vaccine can...

Full description

Saved in:
Bibliographic Details
Published in:Science (American Association for the Advancement of Science) 2003-06, Vol.300 (5628), p.2036-2039
Main Authors: Klausner, Richard D, Fauci, Anthony S, Corey, Lawrence, Nabel, Gary J, Gayle, Helene, Berkley, Seth, Haynes, Barton F, Baltimore, David, Collins, Chris, Douglas, R Gordon, Esparza, Jose, Francis, Donald P, Ganguly, N K, Gerberding, Julie Louise, Johnston, Margaret I, Kazatchkine, Michel D, McMichael, Andrew J, Makgoba, Malegapuru W, Pantaleo, Giuseppe, Piot, Peter, Shao, Yiming, Tramont, Edmund, Varmus, Harold, Wasserheit, Judith N
Format: Article
Language:English
Subjects:
Academies and Institutes - economics
Academies and Institutes - organization & administration
AIDS Vaccines - administration & dosage
AIDS Vaccines - economics
AIDS Vaccines - immunology
Biotechnology - economics
Clinical Trials as Topic - standards
Drug Design
Drug Evaluation, Preclinical - standards
Drug Industry - economics
Financial Support
Global Health
HIV Infections - prevention & control
HIV-1 - immunology
Humans
Intellectual Property
International Cooperation
Multicenter Studies as Topic
Private Sector
Public Policy
Public Sector
Research Support as Topic
Vaccination
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:A new collaborative model of research is needed to increase resources, to prioritize the R (ii) to increase the pace, reduce the overlap, and more systematically explore the elements of and delivery systems for vaccines; (iii) to use common standards for the prompt comparative testing of vaccine candidates; (iv) to expand resources for manufacturing vaccine candidates to speed their use in human trials; and (v) to increase the capacity for international clinical trials and to focus this effort toward quickly measuring the effectiveness of vaccine protection as prototype vaccine candidates are identified.
ISSN:1095-9203